AGREEMENT ---------Registration Rights Agreement • May 1st, 2006 • Soon Shiong Patrick • Pharmaceutical preparations
Exhibit 6 JOINT FILING AGREEMENT ---------------------- PURSUANT TO RULE 13d-1(k) ------------------------- The undersigned acknowledge and agree that the foregoing statement of Schedule 13D is filed on behalf of each of the undersigned and that all...Joint Filing Agreement • May 1st, 2006 • Soon Shiong Patrick • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement of Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 23rd, 2007 • Soon Shiong Patrick • Pharmaceutical preparations
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of November 13, 2007 by and among New Abraxis, Inc. (the “Company”), a Delaware corporation and currently a wholly-owned subsidiary of APP Pharmaceuticals, Inc., APP Pharmaceuticals, Inc. (f/k/a Generico Holdings, Inc.) (“Gholdco”), Dr. Patrick Soon-Shiong (“PSS”) and certain stockholders of Gholdco receiving Common Stock in the Spin-off (each as defined below) who execute and deliver a counterpart to this Agreement (collectively, the “Stockholder Parties”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 24th, 2014 • Soon-Shiong Patrick • Services-commercial physical & biological research • California
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is dated this 14th day of December, 2014, by and between SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and CAMBRIDGE EQUITIES, LP (the “Purchaser”).
June 30, 2016 Sorrento Therapeutics, Inc.Letter Agreement • July 11th, 2016 • Soon-Shiong Patrick • Services-commercial physical & biological research • California
FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 24th, 2014 • Soon-Shiong Patrick • Services-commercial physical & biological research • California
This Amendment (the “Amendment”), made and entered into this 22nd day of December, 2014, by and between by Sorrento Therapeutics, Inc., a Delaware corporation (“Company”) and Cambridge Equities LP (the “Purchaser”), amends that certain securities purchase agreement, dated December 14, 2014, by and between the Company and the Purchaser (“Purchase Agreement”).
JOINT FILING AGREEMENTJoint Filing Agreement • July 15th, 2013 • Soon Shiong Patrick • Games, toys & children's vehicles (no dolls & bicycles)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • July 10th, 2008 • Soon Shiong Patrick • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement of Schedule 13D/A is filed on behalf of each of the undersigned and that all subsequent amendments to this Schedule 13D/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate.
JOINT FILING AGREEMENTJoint Filing Agreement • December 21st, 2015 • Soon-Shiong Patrick • Services-commercial physical & biological research
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
REGISTRATION RIGHTS AGREEMENT September 12, 2012Registration Rights Agreement • July 15th, 2013 • Soon Shiong Patrick • Games, toys & children's vehicles (no dolls & bicycles) • Delaware
The parties to this Registration Rights Agreement (this “Agreement”) are JAKKS PACIFIC, INC., a Delaware corporation (the “Company”), and NANTWORKS LLC, a Delaware limited liability company (the “Purchaser”).
Exhibit 2 ESCROW AGREEMENT This Escrow Agreement (this "ESCROW AGREEMENT"), is dated as of April 18, 2006, by and among American Pharmaceutical Partners, Inc., a Delaware corporation (the "COMPANY"), Dr. Patrick Soon-Shiong, solely in his capacity as...Escrow Agreement • May 1st, 2006 • Soon Shiong Patrick • Pharmaceutical preparations • Delaware
JOINT FILING AGREEMENTJoint Filing Agreement • December 24th, 2014 • Soon-Shiong Patrick • Services-commercial physical & biological research
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • November 25th, 2015 • Soon-Shiong Patrick • Games, toys & children's vehicles (no dolls & bicycles)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
COMMON STOCK PURCHASE WARRANT SORRENTO THERAPEUTICS, INC.Soon-Shiong Patrick • December 24th, 2014 • Services-commercial physical & biological research
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cambridge Equities, LP or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time on or after December 22, 2014 (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), up to 1,724,138 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
JAKKS PACIFIC, INC. Warrant for the Purchase of Common Stock, par value $0.001 per shareSoon Shiong Patrick • July 15th, 2013 • Games, toys & children's vehicles (no dolls & bicycles) • Delaware
THIS CERTIFIES that, for good and valuable consideration, NantWorks LLC, a Delaware limited liability company (together with its successors and assigns, the “Holder”), with an address at 11755 Wilshire Blvd, Suite 200, Los Angeles, CA 90025, is entitled to subscribe for and purchase from JAKKS Pacific, Inc. (the “Company”), upon the terms and conditions set forth herein, in whole or in part, at any time, or from time to time, after September 12, 2012 and before 5:00 p.m. Eastern time on September 12, 2017 (the “Exercise Period”), 1,500,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a price per share equal to the volume-weighted average price of the Company’s Common Stock over the five (5) trading days prior to the date hereof (the “Initial Exercise Price”), as same may be adjusted as provided for herein (the “Warrant Shares”).
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • November 23rd, 2007 • Soon Shiong Patrick • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement of Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate.
CERTIFICATION AND AGREEMENTCertification and Agreement • December 21st, 2015 • Soon-Shiong Patrick • Services-commercial physical & biological research • California
THIS CERTIFICATION AND AGREEMENT (this “Agreement”) is dated this 17th day of December, 2015 (the “Effective Date”), by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Company”), Patrick Soon-Shiong, M.D. (“Soon-Shiong”), CAMBRIDGE EQUITIES, LP (the “Cambridge”), MP 13 Ventures, LLC (“MP 13”), and CHAN SOON-SHIONG FAMILY FOUNDATION (the “Foundation”). Soon-Shiong, Cambridge, MP 13 and the Foundation are referred to herein collectively as the “Soon-Shiong Affiliates”.
CORPORATE GOVERNANCE AND VOTING AGREEMENTPrivileged and Confidential Execution • May 1st, 2006 • Soon Shiong Patrick • Pharmaceutical preparations • Delaware
AGREEMENTAgreement • May 1st, 2006 • Soon Shiong Patrick • Pharmaceutical preparations • Delaware
